MAPKK inhibitors (UCB/Domainex)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug NameMAPKK inhibitors (UCB/Domainex)
Drug Alias Namemitogen-activated protein kinase kinase inhibitors (UCB/Domainex)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDual specificity mitogen-activated protein kinase kinase inhibitors
TargetsDual specificity mitogen-activated protein kinase kinase
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited Kingdom
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesUcb Sa
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesUcb SaDomainex Ltd
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A